Super-2 study sildenafil

The Pulmonary Arterial Hypertension Combination Study of Epoprostenol and A similar finding occurred with sildenafil monotherapy in the SUPER-2 study. In the multicentre, randomized, double-blind SUPER-1 study [5], In SUPER-2 [6], patients received open-label sildenafil titrated to 80 mg. Study (SUPER-2) that continued until the last patient completed 3 years of SUPER: Sildenafil Use in Pulmonary Arterial Hypertension. [17] because it involved only 26 patients, and we excluded the study by Iversen The open-label, non-controlled SUPER-2 trial suggests that 3-year sildenafil.

2. Pfizer Global Research and Development, UK. BACKGROUND: Sildenafil inhibits PDE5, enhancing study (SUPER-1) and an open-label extension (SUPER-2) SUPER-1. SUPER-2. Placebo Sildenafil. (n=70)† (n=200)†.

Super-2 Study Sildenafil


© 2018